Heska (HSKA) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price targets for Heska's stock. Their HSKA share price forecasts range from $120.00 to $150.00. On average, they predict the company's stock price to reach $137.25 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts.

Heska's stock was trading at $62.16 on January 1st, 2023. Since then, HSKA stock has increased by 92.8% and is now trading at $119.84.
View the best growth stocks for 2023 here.

Heska saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,060,000 shares, an increase of 24.6% from the April 30th total of 850,800 shares. Based on an average daily volume of 266,700 shares, the short-interest ratio is currently 4.0 days. Currently, 10.6% of the shares of the stock are sold short.
View Heska's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our HSKA earnings forecast.

Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analysts' expectations of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 7.86%. The company's revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.25) EPS.

ETFs with the largest weight of Heska (NASDAQ:HSKA) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), ProShares Pet Care ETF (PAWZ), SPDR S&P Health Care Equipment ETF (XHE), Motley Fool Mid-Cap Growth ETF (TMFM), Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV) and Principal Healthcare Innovators ETF (BTEC).

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Heska's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.20%), Fred Alger Management LLC (7.59%), Ameriprise Financial Inc. (5.29%), State Street Corp (3.98%), abrdn plc (3.35%) and Riverbridge Partners LLC (2.83%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends.

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSKA stock can currently be purchased for approximately $119.84.

Heska (NASDAQ:HSKA) has a market capitalization of $1.31 billion and generates $257.31 million in revenue each year. The medical research company earns $-19,890,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

The company employs 655 workers across the globe.

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.